<p>Ventyx Biosciences, Inc.（纳斯达克代码：VTYX - 免费报告）- HC Wainwright 的研究分析师在 1 月 8 日星期四发布的研究报告中下调了对 Ventyx Biosciences 2029 财年的每股收益（EPS）预期。HC Wainwright 分析师 E. Bodnar 现在预计该公司将在本年度发布每股收益（$1.57），低于之前预测的（$1.50）。HC Wainwright 对该股票给予 “中性” 评级，目标价为 $14.00。市场普遍预计 Ventyx Biosciences 当前全年的每股收益为（$2.09）。</p>
<p>获取 <strong>Ventyx Biosciences</strong> 的提醒：</p>
<p>Ventyx Biosciences（纳斯达克代码：VTYX - 获取免费报告）最近在 11 月 6 日星期四发布了季度财报。该公司报告季度每股收益为（$0.32），超出市场普遍预期的（$0.45）$0.13。</p>
<p>VTYX 近期成为多个报告的主题。Oppenheimer 在周四的研究报告中将 Ventyx Biosciences 的股票评级从 “跑赢大盘” 下调至 “市场表现”。Lifesci Capital 在周四的报告中重申了 “市场表现” 评级，并将 Ventyx Biosciences 的股票目标价设定为 $14.00。瑞银集团在周四的研究报告中重申了 “中性” 评级，并将 Ventyx Biosciences 的股票目标价下调至 $14.00（之前为 $20.00）。Canaccord Genuity Group 在周四的研究报告中将 Ventyx Biosciences 的评级从 “买入” 下调至 “持有”，并将其目标价从 $16.00 降至 $14.00。最后，Clear Str 在 1 月 7 日星期三的研究报告中将 Ventyx Biosciences 的评级从 “强力买入” 下调至 “持有”。八位研究分析师对该股票给予 “持有” 评级，一位分析师对该公司的股票给予 “卖出” 评级。根据 MarketBeat.com 的数据，Ventyx Biosciences 的平均评级为 “减持”，共识目标价为 $14.86。</p>
<p><strong>阅读我们关于 VTYX 的最新研究报告</strong></p>
<h2>Ventyx Biosciences 价格表现</h2>
<p>VTYX 股票在周一开盘价为 $13.81。该公司的市值为 $9.8548 亿，市盈率为 -9.21，贝塔值为 1.23。该公司的 50 日移动平均价格为 $9.27，200 日移动平均价格为 $5.32。Ventyx Biosciences 的 12 个月低点为 $0.78，12 个月高点为 $25.00。</p>
<h2>Ventyx Biosciences 的机构交易</h2>
<p>几家对冲基金最近调整了对 VTYX 的持股。CWM LLC 在第二季度增持了 Ventyx Biosciences 的股份，增幅为 7.6%。CWM LLC 现在拥有 57,145 股该公司的股票，价值 $122,000，此前在上个季度购买了额外的 4,057 股。Wealth Enhancement Advisory Services LLC 在第二季度增持了 Ventyx Biosciences 的股份，增幅为 21.1%。Wealth Enhancement Advisory Services LLC 现在拥有 29,657 股该公司的股票，价值 $62,000，此前在上个季度购买了额外的 5,174 股。Prelude Capital Management LLC 在第三季度增持了 Ventyx Biosciences 的股份，增幅为 35.0%。Prelude Capital Management LLC 现在拥有 21,200 股该公司的股票，价值 $66,000，此前在上个季度购买了额外的 5,500 股。Hudson Bay Capital Management LP 在第二季度购买了 Ventyx Biosciences 的新头寸，价值约 $34,000。最后，Persistent Asset Partners Ltd 在第三季度收购了 Ventyx Biosciences 的新股份，价值约 $51,000。97.88% 的股票由机构投资者和对冲基金持有。</p>
<h2>Ventyx Biosciences 的内部交易</h2>
<p>在其他 Ventyx Biosciences 的新闻中，内部人士 John Nuss 于 12 月 18 日星期四出售了 12,675 股 Ventyx Biosciences 的股票。该股票以平均价格 $7.72 出售，总价值为 $97,851.00。出售后，内部人士持有该公司 489,481 股股票，价值约 $3,778,793.32。此次交易使其持股减少了 2.52%。该交易已在提交给证券交易委员会的文件中披露，可通过 SEC 网站访问。此外，首席执行官 Raju Mohan 于 12 月 18 日星期四出售了 47,345 股该公司的股票。该股票以平均价格 $7.72 出售，总价值为 $365,503.40。交易后，首席执行官持有该公司 2,372,863 股股票，价值 $18,318,502.36。此次交易使其持股减少了 1.96%。有关此次出售的更多细节可在官方 SEC 披露中找到。内部人士持有该公司 18.18% 的股票。</p>
<h2>关于 Ventyx Biosciences 的热门头条</h2>
<p>以下是本周影响 Ventyx Biosciences 的主要新闻故事：</p>
<ul>
<li>积极情绪：Lilly 确认以每股 14.00 美元（总计约 12 亿美元）收购 Ventyx 的最终协议，为股票提供了明确的现金退出和底线，而交易的风险和时间仍然存在不确定性。Lilly 将收购 Ventyx Biosciences</li>
<li>积极情绪：瑞银开始覆盖，给予买入评级和 20.00 美元的目标价，暗示从当前市场水平有显著上行空间，并对 Ventyx 的资产/战略价值向收购方传达信心。瑞银覆盖报告</li>
<li>中性情绪：富国银行重申 “持平” 评级，目标价为 14.00 美元——有效与收购价格一致，暗示在交易考虑之外短期内上行空间有限。富国银行说明</li>
<li>中性情绪：Lifesci Capital 及其相关覆盖在交易价格附近调整为 “市场表现”/“持有”，表明分析师将已宣布的交易视为主要估值锚点。Lifesci/Lifesci Capital 覆盖</li>
<li>消极情绪：多家卖方公司（Oppenheimer、Canaccord Genuity、Clear Street）在交易后下调评级或降低对 VTYX 的热情——这些举动可能会对剩余流通股施加卖压，并反映出对 14 美元报价之外上行空间的担忧。Oppenheimer 下调 Canaccord 下调</li>
<li>消极情绪：多家律师事务所已启动调查和股东警报，指控 Lilly 交易中可能存在不公平程序或价格不足；此类诉讼可能会延迟交易完成，增加交易成本，并增加最终股东回收的不确定性。Kahn Swick &amp; Foti 调查 Edelson Lechtzin 调查</li>
</ul>
<h2>关于 Ventyx Biosciences</h2>
<p>(获取免费报告)</p>
<p>Ventyx Biosciences, Inc 是一家临床阶段的生物制药公司，开发小分子产品候选药物以应对多种炎症性疾病。该公司的主要临床产品候选药物是 VTX958，一种选择性别构酶类型 2 抑制剂，用于治疗银屑病、银屑病关节炎和克罗恩病。它还在开发 VTX002，一种在进行 II 期临床试验的鞘氨醇 1 磷酸受体调节剂，用于治疗溃疡性结肠炎；以及 VTX2735，一种外周靶向 NOD 样受体蛋白 3 炎症小体抑制剂，用于治疗患有冷诱导周期综合症的患者。</p>
<h2>另见</h2>
<ul>
<li>我们更看好的五只股票，胜过 Ventyx Biosciences</li>
<li>巨大的机器人推广正在进行中</li>
<li>请勿删除，立即阅读</li>
<li>免费：可能改变您生活的加密峰会</li>
<li>新黄金价格目标</li>
<li>但在 2026 年 5 月 20 日之前，这只 2 美元的黄金股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VlRZWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VlRZWA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送至 contact@marketbeat.com.</em></p>
<h2>您现在应该投资 1,000 美元于 Ventyx Biosciences 吗？</h2>
<p>在您考虑 Ventyx Biosciences 之前，您需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Ventyx Biosciences 并不在名单上。</p>
<p>尽管 Ventyx Biosciences 目前在分析师中获得了减持评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

VTYX

<p>HC Wainwright 已将 Ventyx Biosciences (NASDAQ:VTYX) 的 2029 财年每股收益预期从 ($1.50) 下调至 ($1.57)。该公司维持 “中性” 评级，目标价为 $14.00。市场普遍预期该公司当前财年的每股收益为 ($2.09)。最近的报告显示，Oppenheimer 和 Canaccord Genuity 下调了评级，而 UBS Group 和 Lifesci Capital 则重申了他们的目标价。VTYX 股票开盘价为 $13.81，市值为 9.8548 亿美元，12 个月高点为 $25.00</p>

<p>Ventyx Biosciences, Inc. (NASDAQ:VTYX - Free Report) - Research analysts at HC Wainwright cut their FY2029 earnings per share (EPS) estimates for Ventyx Biosciences in a research note issued on Thursday, January 8th. HC Wainwright analyst E. Bodnar now expects that the company will post earnings of ($1.57) per share for the year, down from their previous forecast of ($1.50). HC Wainwright has a &#34;Neutral&#34; rating and a $14.00 price objective on the stock. The consensus estimate for Ventyx Biosciences' current full-year earnings is ($2.09) per share.</p>
<div class="lb-trans"><p>Ventyx Biosciences, Inc.（纳斯达克代码：VTYX - 免费报告）- HC Wainwright 的研究分析师在 1 月 8 日星期四发布的研究报告中下调了对 Ventyx Biosciences 2029 财年的每股收益（EPS）预期。HC Wainwright 分析师 E. Bodnar 现在预计该公司将在本年度发布每股收益（$1.57），低于之前预测的（$1.50）。HC Wainwright 对该股票给予 “中性” 评级，目标价为 $14.00。市场普遍预计 Ventyx Biosciences 当前全年的每股收益为（$2.09）。</p>
</div><p>Get <strong>Ventyx Biosciences</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Ventyx Biosciences</strong> 的提醒：</p>
</div><p>Ventyx Biosciences (NASDAQ:VTYX - Get Free Report) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($0.32) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.13.</p>
<div class="lb-trans"><p>Ventyx Biosciences（纳斯达克代码：VTYX - 获取免费报告）最近在 11 月 6 日星期四发布了季度财报。该公司报告季度每股收益为（$0.32），超出市场普遍预期的（$0.45）$0.13。</p>
</div><p>VTYX has been the topic of several other reports. Oppenheimer downgraded shares of Ventyx Biosciences from an &#34;outperform&#34; rating to a &#34;market perform&#34; rating in a research report on Thursday. Lifesci Capital reissued a &#34;market perform&#34; rating and set a $14.00 price target on shares of Ventyx Biosciences in a report on Thursday. UBS Group restated a &#34;neutral&#34; rating and issued a $14.00 price target (down previously from $20.00) on shares of Ventyx Biosciences in a research report on Thursday. Canaccord Genuity Group downgraded Ventyx Biosciences from a &#34;buy&#34; rating to a &#34;hold&#34; rating and reduced their price objective for the company from $16.00 to $14.00 in a research note on Thursday. Finally, Clear Str cut Ventyx Biosciences from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research report on Wednesday, January 7th. Eight research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, Ventyx Biosciences has an average rating of &#34;Reduce&#34; and a consensus target price of $14.86.</p>
<div class="lb-trans"><p>VTYX 近期成为多个报告的主题。Oppenheimer 在周四的研究报告中将 Ventyx Biosciences 的股票评级从 “跑赢大盘” 下调至 “市场表现”。Lifesci Capital 在周四的报告中重申了 “市场表现” 评级，并将 Ventyx Biosciences 的股票目标价设定为 $14.00。瑞银集团在周四的研究报告中重申了 “中性” 评级，并将 Ventyx Biosciences 的股票目标价下调至 $14.00（之前为 $20.00）。Canaccord Genuity Group 在周四的研究报告中将 Ventyx Biosciences 的评级从 “买入” 下调至 “持有”，并将其目标价从 $16.00 降至 $14.00。最后，Clear Str 在 1 月 7 日星期三的研究报告中将 Ventyx Biosciences 的评级从 “强力买入” 下调至 “持有”。八位研究分析师对该股票给予 “持有” 评级，一位分析师对该公司的股票给予 “卖出” 评级。根据 MarketBeat.com 的数据，Ventyx Biosciences 的平均评级为 “减持”，共识目标价为 $14.86。</p>
</div><p><strong>Read Our Latest Research Report on VTYX</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 VTYX 的最新研究报告</strong></p>
</div><h2>Ventyx Biosciences Price Performance</h2>
<div class="lb-trans"><h2>Ventyx Biosciences 价格表现</h2>
</div><p>VTYX stock opened at $13.81 on Monday. The company has a market cap of $985.48 million, a price-to-earnings ratio of -9.21 and a beta of 1.23. The company has a fifty day moving average price of $9.27 and a 200 day moving average price of $5.32. Ventyx Biosciences has a 12 month low of $0.78 and a 12 month high of $25.00.</p>
<div class="lb-trans"><p>VTYX 股票在周一开盘价为 $13.81。该公司的市值为 $9.8548 亿，市盈率为 -9.21，贝塔值为 1.23。该公司的 50 日移动平均价格为 $9.27，200 日移动平均价格为 $5.32。Ventyx Biosciences 的 12 个月低点为 $0.78，12 个月高点为 $25.00。</p>
</div><h2>Institutional Trading of Ventyx Biosciences</h2>
<div class="lb-trans"><h2>Ventyx Biosciences 的机构交易</h2>
</div><p>Several hedge funds have recently modified their holdings of VTYX. CWM LLC boosted its stake in shares of Ventyx Biosciences by 7.6% during the 2nd quarter. CWM LLC now owns 57,145 shares of the company's stock worth $122,000 after purchasing an additional 4,057 shares during the last quarter. Wealth Enhancement Advisory Services LLC raised its position in shares of Ventyx Biosciences by 21.1% in the second quarter. Wealth Enhancement Advisory Services LLC now owns 29,657 shares of the company's stock valued at $62,000 after buying an additional 5,174 shares during the last quarter. Prelude Capital Management LLC raised its position in shares of Ventyx Biosciences by 35.0% in the third quarter. Prelude Capital Management LLC now owns 21,200 shares of the company's stock valued at $66,000 after buying an additional 5,500 shares during the last quarter. Hudson Bay Capital Management LP purchased a new position in shares of Ventyx Biosciences during the second quarter valued at approximately $34,000. Finally, Persistent Asset Partners Ltd acquired a new stake in Ventyx Biosciences during the third quarter worth approximately $51,000. 97.88% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>几家对冲基金最近调整了对 VTYX 的持股。CWM LLC 在第二季度增持了 Ventyx Biosciences 的股份，增幅为 7.6%。CWM LLC 现在拥有 57,145 股该公司的股票，价值 $122,000，此前在上个季度购买了额外的 4,057 股。Wealth Enhancement Advisory Services LLC 在第二季度增持了 Ventyx Biosciences 的股份，增幅为 21.1%。Wealth Enhancement Advisory Services LLC 现在拥有 29,657 股该公司的股票，价值 $62,000，此前在上个季度购买了额外的 5,174 股。Prelude Capital Management LLC 在第三季度增持了 Ventyx Biosciences 的股份，增幅为 35.0%。Prelude Capital Management LLC 现在拥有 21,200 股该公司的股票，价值 $66,000，此前在上个季度购买了额外的 5,500 股。Hudson Bay Capital Management LP 在第二季度购买了 Ventyx Biosciences 的新头寸，价值约 $34,000。最后，Persistent Asset Partners Ltd 在第三季度收购了 Ventyx Biosciences 的新股份，价值约 $51,000。97.88% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>Insider Transactions at Ventyx Biosciences</h2>
<div class="lb-trans"><h2>Ventyx Biosciences 的内部交易</h2>
</div><p>In other Ventyx Biosciences news, insider John Nuss sold 12,675 shares of Ventyx Biosciences stock in a transaction that occurred on Thursday, December 18th. The stock was sold at an average price of $7.72, for a total value of $97,851.00. Following the sale, the insider owned 489,481 shares of the company's stock, valued at approximately $3,778,793.32. The trade was a 2.52% decrease in their position. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which can be accessed through the SEC website. Also, CEO Raju Mohan sold 47,345 shares of the business's stock in a transaction that occurred on Thursday, December 18th. The stock was sold at an average price of $7.72, for a total value of $365,503.40. Following the transaction, the chief executive officer owned 2,372,863 shares in the company, valued at $18,318,502.36. The trade was a 1.96% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 18.18% of the company's stock.</p>
<div class="lb-trans"><p>在其他 Ventyx Biosciences 的新闻中，内部人士 John Nuss 于 12 月 18 日星期四出售了 12,675 股 Ventyx Biosciences 的股票。该股票以平均价格 $7.72 出售，总价值为 $97,851.00。出售后，内部人士持有该公司 489,481 股股票，价值约 $3,778,793.32。此次交易使其持股减少了 2.52%。该交易已在提交给证券交易委员会的文件中披露，可通过 SEC 网站访问。此外，首席执行官 Raju Mohan 于 12 月 18 日星期四出售了 47,345 股该公司的股票。该股票以平均价格 $7.72 出售，总价值为 $365,503.40。交易后，首席执行官持有该公司 2,372,863 股股票，价值 $18,318,502.36。此次交易使其持股减少了 1.96%。有关此次出售的更多细节可在官方 SEC 披露中找到。内部人士持有该公司 18.18% 的股票。</p>
</div><h2>Trending Headlines about Ventyx Biosciences</h2>
<div class="lb-trans"><h2>关于 Ventyx Biosciences 的热门头条</h2>
</div><p>Here are the key news stories impacting Ventyx Biosciences this week:</p>
<div class="lb-trans"><p>以下是本周影响 Ventyx Biosciences 的主要新闻故事：</p>
</div><ul>
<li>Positive Sentiment: Lilly confirms definitive agreement to acquire Ventyx for $14.00 per share (≈$1.2B total), providing a clear cash exit and a floor under the stock while closing risk and timing remain uncertainties. Lilly to acquire Ventyx Biosciences</li>
<li>Positive Sentiment: UBS begins coverage with a Buy rating and $20.00 price target, implying material upside from the current market level and signaling confidence in Ventyx’s assets/strategic value to acquirers. UBS coverage reported</li>
<li>Neutral Sentiment: Wells Fargo reaffirmed an &#34;equal weight&#34; rating with a $14.00 price target — effectively in line with the acquisition price and suggesting limited near-term upside beyond the deal consideration. Wells Fargo note</li>
<li>Neutral Sentiment: Lifesci Capital and Lifesci-related coverage moved to &#34;market perform&#34;/&#34;hold&#34; around the deal price, indicating analysts are treating the announced transaction as the primary valuation anchor. Lifesci/Lifesci Capital coverage</li>
<li>Negative Sentiment: Several sell-side firms (Oppenheimer, Canaccord Genuity, Clear Street) issued downgrades or cut enthusiasm for VTYX after the deal — moves that can add selling pressure on any remaining float and reflect concerns about upside beyond the $14 offer. Oppenheimer downgradeCanaccord downgrade</li>
<li>Negative Sentiment: Multiple law firms have launched investigations and shareholder alerts alleging possible unfair process or inadequate price in the Lilly deal; such litigation can delay closing, raise transaction costs, and add uncertainty around final shareholder recoveries. Kahn Swick &amp; Foti investigationEdelson Lechtzin investigation</li>
</ul>
<div class="lb-trans"><ul>
<li>积极情绪：Lilly 确认以每股 14.00 美元（总计约 12 亿美元）收购 Ventyx 的最终协议，为股票提供了明确的现金退出和底线，而交易的风险和时间仍然存在不确定性。Lilly 将收购 Ventyx Biosciences</li>
<li>积极情绪：瑞银开始覆盖，给予买入评级和 20.00 美元的目标价，暗示从当前市场水平有显著上行空间，并对 Ventyx 的资产/战略价值向收购方传达信心。瑞银覆盖报告</li>
<li>中性情绪：富国银行重申 “持平” 评级，目标价为 14.00 美元——有效与收购价格一致，暗示在交易考虑之外短期内上行空间有限。富国银行说明</li>
<li>中性情绪：Lifesci Capital 及其相关覆盖在交易价格附近调整为 “市场表现”/“持有”，表明分析师将已宣布的交易视为主要估值锚点。Lifesci/Lifesci Capital 覆盖</li>
<li>消极情绪：多家卖方公司（Oppenheimer、Canaccord Genuity、Clear Street）在交易后下调评级或降低对 VTYX 的热情——这些举动可能会对剩余流通股施加卖压，并反映出对 14 美元报价之外上行空间的担忧。Oppenheimer 下调 Canaccord 下调</li>
<li>消极情绪：多家律师事务所已启动调查和股东警报，指控 Lilly 交易中可能存在不公平程序或价格不足；此类诉讼可能会延迟交易完成，增加交易成本，并增加最终股东回收的不确定性。Kahn Swick &amp; Foti 调查 Edelson Lechtzin 调查</li>
</ul>
</div><h2>About Ventyx Biosciences</h2>
<div class="lb-trans"><h2>关于 Ventyx Biosciences</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome.</p>
<div class="lb-trans"><p>Ventyx Biosciences, Inc 是一家临床阶段的生物制药公司，开发小分子产品候选药物以应对多种炎症性疾病。该公司的主要临床产品候选药物是 VTX958，一种选择性别构酶类型 2 抑制剂，用于治疗银屑病、银屑病关节炎和克罗恩病。它还在开发 VTX002，一种在进行 II 期临床试验的鞘氨醇 1 磷酸受体调节剂，用于治疗溃疡性结肠炎；以及 VTX2735，一种外周靶向 NOD 样受体蛋白 3 炎症小体抑制剂，用于治疗患有冷诱导周期综合症的患者。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Ventyx Biosciences</li>
<li>Huge robotics rollout underway</li>
<li>Do not delete, read immediately</li>
<li>Free: The Crypto Summit That Could Change Your Life</li>
<li>New gold price target</li>
<li>But this $2 Gold Stock Before May 20, 2026</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过 Ventyx Biosciences</li>
<li>巨大的机器人推广正在进行中</li>
<li>请勿删除，立即阅读</li>
<li>免费：可能改变您生活的加密峰会</li>
<li>新黄金价格目标</li>
<li>但在 2026 年 5 月 20 日之前，这只 2 美元的黄金股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VlRZWA" alt="" original-src="https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx?Prefix=NASDAQ&amp;Symbol=VTYX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Ventyx Biosciences Right Now?</h2>
<div class="lb-trans"><h2>您现在应该投资 1,000 美元于 Ventyx Biosciences 吗？</h2>
</div><p>Before you consider Ventyx Biosciences, you'll want to hear this.</p>
<div class="lb-trans"><p>在您考虑 Ventyx Biosciences 之前，您需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ventyx Biosciences wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Ventyx Biosciences 并不在名单上。</p>
</div><p>While Ventyx Biosciences currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>尽管 Ventyx Biosciences 目前在分析师中获得了减持评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

HC Wainwright 对 Ventyx Biosciences 2029 财年的收益预估为负